Liberum Capital reaffirmed their hold rating on shares of Shire PLC (LON:SHP) in a research note published on Thursday. They currently have a GBX 4,900 ($64.64) price target on the biopharmaceutical company’s stock.
Other equities analysts have also issued research reports about the stock. Jefferies Group LLC reaffirmed a buy rating and set a GBX 6,400 ($84.42) price objective on shares of Shire PLC in a research report on Wednesday, May 3rd. Shore Capital reaffirmed a buy rating on shares of Shire PLC in a research report on Wednesday, June 21st. HSBC Holdings plc raised shares of Shire PLC to a hold rating and set a GBX 4,450 ($58.70) price objective on the stock in a research report on Thursday, July 6th. Royal Bank Of Canada reaffirmed an outperform rating on shares of Shire PLC in a research report on Friday, July 7th. Finally, J P Morgan Chase & Co reaffirmed an overweight rating and set a GBX 6,000 ($79.15) price objective on shares of Shire PLC in a research report on Tuesday, July 11th. Three investment analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the stock. The stock currently has an average rating of Buy and an average target price of GBX 5,957.88 ($78.59).
Shares of Shire PLC (SHP) opened at 4018.50 on Thursday. Shire PLC has a 1-year low of GBX 3,957.00 and a 1-year high of GBX 5,377.00. The stock’s market capitalization is GBX 36.33 billion. The firm’s 50-day moving average is GBX 4,283.27 and its 200 day moving average is GBX 4,548.83.
WARNING: “Liberum Capital Reaffirms Hold Rating for Shire PLC (SHP)” was reported by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this piece on another website, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece can be read at https://stocknewstimes.com/2017/08/06/liberum-capital-reaffirms-hold-rating-for-shire-plc-shp.html.
In other Shire PLC news, insider Dominic Blakemore purchased 152 shares of the firm’s stock in a transaction on Friday, June 30th. The shares were purchased at an average price of GBX 4,255 ($56.13) per share, for a total transaction of £6,467.60 ($8,531.33).
Shire PLC Company Profile
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.
